Felipe De Los Rios La Rosa
Overview
Explore the profile of Felipe De Los Rios La Rosa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
870
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Dittmar E, Wolfel T, Menendez L, Pozo J, Ramirez M, Belnap S, et al.
Ann Pharmacother
. 2023 Jan;
57(10):1147-1153.
PMID: 36688289
Background: Recent evidence suggests tenecteplase at an intravenous dose of 0.25 mg/kg is as safe and efficacious as intravenous alteplase standard dose and demonstrates a more favorable pharmacokinetic profile for...
12.
Rubens M, Saxena A, Ramamoorthy V, Ahmed M, Zhang Z, McGranaghan P, et al.
Brain Sci
. 2022 Sep;
12(9).
PMID: 36138913
Coronavirus disease 2019 (COVID-19) could be a risk factor for acute ischemic stroke (AIS) due to the altered coagulation process and hyperinflammation. This study examined the risk factors, clinical profile,...
13.
Robinson D, Stanton R, Sucharew H, Alwell K, Haverbusch M, De Los Rios La Rosa F, et al.
Neurology
. 2022 Aug;
99(22):e2464-e2473.
PMID: 36041865
Background And Objective: There are significant racial disparities in stroke in the United States, with Black individuals having a higher risk of incident stroke even when adjusted for traditional stroke...
14.
Madsen T, Cummings O, De Los Rios La Rosa F, Khoury J, Alwell K, Woo D, et al.
Stroke
. 2022 Jul;
53(10):3082-3090.
PMID: 35862206
Background: Though stroke risk factors such as substance use may vary with age, less is known about trends in substance use over time or about performance of toxicology screens in...
15.
16.
Baker A, Schwamm L, Sanborn D, Furie K, Stretz C, Mac Grory B, et al.
Stroke
. 2022 Jan;
53(6):1883-1891.
PMID: 35086361
Background: There are limited data about the epidemiology and secondary stroke prevention strategies used for patients with depressed left ventricular ejection fraction (LVEF) and sinus rhythm following an acute ischemic...
17.
Martin Diaz C, Guizan Corrales E, Belnap S, Kline J, Gopalani R, Marrero S, et al.
Cureus
. 2021 Sep;
13(8):e17392.
PMID: 34584802
Objective To assess anticoagulation (AC) timing and appropriateness in patients with acute ischemic stroke (AIS) or transient ischemic attack (TIA) due to atrial fibrillation (AF) in a predominantly Hispanic community...
18.
Greenwood J, Belnap S, Dabus G, Linfante I, De Los Rios La Rosa F
Clin Neurol Neurosurg
. 2021 Jul;
207:106793.
PMID: 34225003
Background: It is unclear how interventions designed to restrict community and in-hospital exposure to the SARS-CoV-2 (COVID-19) virus influenced stroke care for patients seeking acute treatment. Therefore, we aimed to...
19.
Ravipati K, Guillen R, Belnap S, Saxena A, Veledar E, Starosciak A, et al.
Thromb Res
. 2021 Jun;
204:76-80.
PMID: 34153647
Background: IV alteplase is a primary treatment for acute ischemic stroke (AIS) at a weight-based dose (WBD) of 0.9 mg/kg and maximum dose (MD) of 90 mg. There are conflicting...
20.
Sucharew H, Kleindorfer D, Khoury J, Alwell K, Haverbusch M, Stanton R, et al.
Cerebrovasc Dis
. 2021 Jun;
50(5):567-573.
PMID: 34107479
No abstract available.